The spotlight was on anti-interleukin drugs at the Madrid meeting last week, especially their role in advancing the treatment of psoriatic arthritis.
Johnson & Johnson’s Tremfya has moved closer to joining other interleukin inhibitors in the psoriatic arthritis (PsA) space after promising late-stage data of the drug was presented at the European League Against Rheumatism congress in Madrid.
The healthcare giant unveiled topline data on 14 June from the DISCOVER-1 and DISCOVER-2 Phase III trials of Tremfya (guselkumab) in adults with moderate to severe active PsA
The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.
Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.
Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.
Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ‘historic economic prosperity deal’ does not include the sector.
